Cell therapy weekly: first patient receives stem cell therapy in Phase III Parkinson’s disease trial
The first patient has been treated in BlueRock Therapeutics’ Phase III trial, exPDdite-2, evaluating bemdaneprocel for Parkinson’s disease.
September 25, 2025